Viewing Study NCT05248659


Ignite Creation Date: 2025-12-24 @ 3:06 PM
Ignite Modification Date: 2025-12-27 @ 9:12 PM
Study NCT ID: NCT05248659
Status: ENROLLING_BY_INVITATION
Last Update Posted: 2024-12-09
First Post: 2022-02-18
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Phase 2/3 Open-Label Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module